Black Diamond Therapeutics (BDTX) Change in Account Payables: 2019-2021
Historic Change in Account Payables for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$694,000.
- Black Diamond Therapeutics' Change in Account Payables fell 51.20% to -$694,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $1.6 million, marking a year-over-year increase of 46.77%. This contributed to the annual value of $1.7 million for FY2024, which is 181.91% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Change in Account Payables of -$694,000 as of Q4 2021, which was down 210.51% from $628,000 recorded in Q3 2021.
- Black Diamond Therapeutics' 5-year Change in Account Payables high stood at $2.9 million for Q3 2020, and its period low was -$3.8 million during Q2 2020.
- Moreover, its 3-year median value for Change in Account Payables was $275,000 (2019), whereas its average is $341,000.
- Within the past 5 years, the most significant YoY rise in Black Diamond Therapeutics' Change in Account Payables was 4,533.33% (2020), while the steepest drop was 1,258.33% (2020).
- Over the past 3 years, Black Diamond Therapeutics' Change in Account Payables (Quarterly) stood at $958,000 in 2019, then tumbled by 147.91% to -$459,000 in 2020, then slumped by 51.20% to -$694,000 in 2021.
- Its Change in Account Payables was -$694,000 in Q4 2021, compared to $628,000 in Q3 2021 and -$356,000 in Q2 2021.